APOB and atherosclerosis: In summary, among very high risk individuals with T2DM and ASCVD who had elevated non-HDL-C (DM-DYSLIPIDEMIA) or LDL-C (DM-INSULIN) levels despite maximally tolerated statins, alirocumab significantly reduced atherogenic cholesterol and improved achievement of LDL-C, non-HDL-C, and ApoB goals versus controls.